CRISPR patent dispute to be decided on legal technicality

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

The U.S. Patent Office will now resolve a dispute over one of the hottest biotech breakthrough of the decade, the genome-editing technology Crispr/Cas9, through an arcane proceeding that technically should no longer exist. Because the disputed patents date back to just before a new law took effect in 2013, the patent office will work out who gets credit for inventing Crispr via a so-called interference proceeding—probably one of the last such proceedings ever.

Even outdated patent laws like to go out with a bang.

And what a bang it could be, given the billion-dollar implications. Crispr/Cas9 allows scientists to precisely manipulate genes in any living thing, including humans. If the implications bear out, that could mean cures for diseases, famine- and climate-proof food crops, and all sorts of other science-fiction outcomes. UC Berkeley and the Broad Institute in Cambridge, Massachusetts both have researchers with claim to the creation of the world-changing invention.

Read full, original post: An arcane patent law may decide CRISPR’s big legal fight

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
screenshot at  pm

Are pesticide residues on food something to worry about?

In 1962, Rachel Carson’s Silent Spring drew attention to pesticides and their possible dangers to humans, birds, mammals and the ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.